Cited by 516Chronic Obstructive Pulmonary Disease (COPD) ResearchMedication Adherence and ComplianceInhalation and Respiratory Drug Delivery

Adherence to inhaled therapy, mortality and hospital admission in COPD

Open access
Vestbo, J, Anderson, J A, Calverley, P M A, Celli, B, Ferguson, G T, Jenkins, C, Knobil, K, Willits, L R +2 more·2009·Thorax

Abstract

BACKGROUND: Little is known about adherence to inhaled medication in chronic obstructive pulmonary disease (COPD) and the impact on mortality and morbidity. METHODS: Data on drug adherence from a randomised double-blind trial comparing inhaled salmeterol 50 microg + fluticasone propionate 500 microg twice daily with placebo and each drug individually in 6112 patients with moderate to severe COPD over 3 years in the TORCH study were used. All-cause mortality and exacerbations leading to hospital admission were primary and secondary end points. The study of adherence was not specified a priori as an ancillary study. RESULTS: Of the 4880 patients (79.8%) with good adherence defined as >80% use of study medication, 11.3% died compared with 26.4% of the 1232 patients (20.2%) with poor adherence. The annual rates of hospital admission for exacerbations were 0.15 and 0.27, respectively. The association between adherence and mortality remained unchanged and statistically significant after adjusting for other factors related to prognosis (hazard ratio 0.40 (95% CI 0.35 to 0.46), p<0.001). The association was even stronger when analysing on-treatment deaths only. Similarly, the association between adherence and hospital admission remained unchanged and significant in a multivariate analysis (rate ratio 0.58 (95% CI 0.44 to 0.73, p<0.001). The association between increased adherence and improved mortality and reduction in hospital admission was independent of study treatment. The effect of treatment was more pronounced in patients with good adherence than in those with poor adherence. CONCLUSION: Adherence to inhaled medication is significantly associated with reduced risk of death and admission to hospital due to exacerbations in COPD. Further research is needed to understand these strong associations.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/thx.2009.113662

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Vestbo, J., Anderson, J. A., Calverley, P. M. A., Celli, B., Ferguson, G. T., Jenkins, C., Knobil, K., Willits, L. R., Yates, J. C., & Jones, P. W.
Affiliations
  • University of Manchester (GB)
  • GlaxoSmithKline (United Kingdom) (GB)
  • Aintree University Hospital (GB)
  • Tufts University (US)
  • Woolcock Institute of Medical Research (AU)
  • GlaxoSmithKline (United States) (US)
  • St George's, University of London (GB)
Corresponding author
Vestbo, J
Venue
Thorax
Publisher
BMJ
Published
2009-08-23
Volume
64
Issue
11
Pages
939-943
ISSN
0040-6376 (ISSN-L)
OpenAlex
W2095666112
Cited by
516
References
32
Citations by year
2026: 17 · 2025: 22 · 2024: 36 · 2023: 35 · 2022: 30 · 2021: 34 · 2020: 45 · 2019: 36 · 2018: 33 · 2017: 32 · 2016: 31 · 2015: 35 · 2014: 45 · 2013: 31 · 2012: 17
FWCI
15.15
Type
journal article
Language
en
Open access
Locations
  • Thorax (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
Keywords
chronic obstructive pulmonary disease, medication adherence, inhalation therapy, salmeterol, fluticasone propionate, all-cause mortality, hospitalization, COPD exacerbations, TORCH trial
MeSH terms
Fluticasone, Salmeterol Xinafoate, Administration, Inhalation, Adult, Aged, Aged, 80 and over, Albuterol, Androstadienes, Bronchodilator Agents, Drug Administration Schedule, Drug Combinations, Drug Therapy, Combination, Epidemiologic Methods, Female, Hospitalization, Humans, Male, Middle Aged, Pulmonary Disease, Chronic Obstructive, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review